# Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation

> **NCT02771054** · PHASE4 · COMPLETED · sponsor: **Göteborg University** · enrollment: 22 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** TAF/FTC

## Key facts

- **NCT ID:** NCT02771054
- **Lead sponsor:** Göteborg University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-02
- **Primary completion:** 2018-07-15
- **Final completion:** 2018-07-15
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02771054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02771054, "Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02771054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*